Enfamil NEC Lawsuit:
Settlement Updates for Families

Enfamil, manufactured by Mead Johnson Nutrition (now owned by British multinational Reckitt Benckiser), is one of the most widely used infant formula brands in the United States. It is also at the center of a massive wave of litigation alleging that its cow’s milk–based formulas cause necrotizing enterocolitis (NEC) in premature infants.

In March 2024, an Illinois jury delivered a landmark $60 million verdict against Mead Johnson — the first major plaintiff verdict in the NEC litigation. Since then, the number of lawsuits has continued to grow, with more than 775 cases now pending in federal and state courts.

This page covers everything families need to know about the Enfamil NEC lawsuit: which products are involved, what verdicts have been reached, the current status of the litigation, and how to find out if you qualify.

Who Owns Enfamil? Understanding Mead Johnson & Reckitt

The corporate history matters because it affects who is liable. Mead Johnson Nutrition originally developed and manufactured Enfamil products. In 2017, the British consumer goods giant Reckitt Benckiser (now known simply as “Reckitt”) acquired Mead Johnson for approximately $17.9 billion.

Both Mead Johnson and Reckitt are named as defendants in the NEC lawsuits. Reckitt has publicly acknowledged the litigation as a significant financial exposure and has set aside reserves for potential NEC-related liabilities.

For families considering legal action, this means there are deep-pocketed defendants with the resources to pay substantial verdicts and settlements.

Which Enfamil Products Are Linked to NEC?

The lawsuits allege that all cow’s milk–based Enfamil formulas pose an elevated NEC risk for premature infants. The specific products most frequently cited in litigation include:

The $60 Million Illinois Verdict

In March 2024, an Illinois jury delivered the first major plaintiff verdict in the NEC litigation. The jury awarded $60 million to the family of a premature infant who developed NEC and died after being fed Enfamil formula in the NICU.

The jury found that Mead Johnson was negligent and failed to warn about the risks of feeding cow’s milk–based formula to premature infants. The verdict included both compensatory damages for the family’s loss and punitive damages to punish Mead Johnson for its conduct.

This verdict was followed in July 2024 by a $495 million verdict against Abbott Laboratories (the maker of Similac) in a Missouri state court case. Together, these two verdicts — totaling more than $555 million — sent a powerful signal that juries are willing to hold formula manufacturers accountable.

Where the Enfamil NEC Lawsuit Stands in 2026

Federal MDL (MDL 3026)

The majority of Enfamil NEC lawsuits are consolidated in MDL 3026 in the U.S. District Court for the Northern District of Illinois, before Judge Rebecca Pallmeyer. As of early 2026, there are approximately 775 pending cases in the MDL, with new cases being filed regularly.

The federal bellwether process has faced challenges. Judge Pallmeyer granted summary judgment in favor of the defense in the first three planned bellwether cases, meaning those cases were dismissed before reaching a jury. However, these rulings are specific to the facts of those individual cases and do not affect the broader litigation.

Upcoming Bellwether Trials

A second wave of bellwether trials is scheduled for 2026 and 2027:

State Court Cases Continue

While the federal MDL process works through bellwether trials, state court cases continue to move forward independently. Both major plaintiff verdicts ($60M in Illinois and $495M in Missouri) came from state court, not the federal MDL. This means families are not limited to the federal process.

Notably, a Missouri judge overturned the only defense verdict in the NEC litigation in March 2025, citing misconduct by defense counsel. This erased the manufacturers’ sole jury win and further strengthened the plaintiffs’ position.

What Mead Johnson Knew — and When

The central allegation in the Enfamil NEC litigation is that Mead Johnson had decades of scientific evidence showing that cow’s milk–based formula significantly increased the risk of NEC in premature infants — and chose not to warn.

Research dating back to the 1990s demonstrated that premature infants fed an exclusive human milk diet had significantly lower rates of NEC compared to those fed cow’s milk–based formula. Major medical organizations, including the American Academy of Pediatrics, have recommended breast milk as the preferred nutrition for premature infants specifically because of the NEC risk.

Despite this knowledge, Mead Johnson continued to aggressively market Enfamil Premature and its other NICU products without adequate warnings about the NEC risk. The lawsuits allege that the company prioritized profits over patient safety.

Is There an Enfamil NEC Settlement?

As of March 2026, there is no global settlement in the Enfamil NEC litigation. Cases are being tried individually in state courts and through bellwether trials in the federal MDL.

The outcome of the upcoming 2026 bellwether trials will likely determine whether Mead Johnson and Reckitt move toward settlement discussions. Historically in mass tort litigation, global settlements tend to emerge after defendants lose multiple jury trials and face mounting financial exposure.

With more than $555 million in plaintiff verdicts already on the books, and additional trials scheduled through 2027, the pressure on manufacturers to negotiate is growing. Families who file now will be positioned to benefit from any future settlement while preserving their right to go to trial.

Do You Qualify for an Enfamil NEC Lawsuit?

If your premature baby developed NEC in the NICU, you may qualify for an Enfamil NEC lawsuit. There is no cost to find out — our case reviews are free and confidential.

Frequently Asked Questions

Related Reading